Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Transplant Infection Clear all

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: Up to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions: tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 40
States / cities: Duarte, California • La Jolla, California • Loma Linda, California + 28 more

Conditions: COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Questionnaire Administration, Sotrovimab, Biospecimen Collection; Other · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bronchiolitis
Interventions: Fluticasone Propionate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Transplant Recipients, Liver Transplant Recipients
Interventions: Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: etanercept, methylprednisolone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more

Conditions: Hepatitis B, HIV Infection
Interventions: Adefovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Transplant Infection
Interventions: Tolsura; Drug
Lead sponsor: Hong Nguyen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C
Interventions: Mavyret; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hepatitis C, Chronic; AUD
Interventions: Brief alcohol counseling, Group and Individual Therapy Sessions; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • West Hollywood, California + 2 more

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatitis C, Chronic, Lung Transplant
Interventions: Epclusa; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cytomegalovirus Infections
Interventions: valganciclovir [Valcyte]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • Durham, North Carolina + 2 more

Conditions: Lung Transplantation, Respiratory Tract Infections, Pulmonary Infection
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: COVID-19, Kidney Transplant
Interventions: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: Blastomycosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Birmingham, Alabama • Bethesda, Maryland

Conditions: Lung Transplant, Bronchiolitis Obliterans, Obliterative Bronchiolitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Gram-Negative Bacterial Infections, Gram-negative Bacteremia, Multidrug-Resistant Organism, Hospital-acquired Pneumonia, Healthcare-associated Pneumonia
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Sinusitis
Interventions: dupilumab, placebo; Biological · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Influenza Vaccine in Lung Transplant Patients

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

COVID Protection After Transplant-Immunosuppression Reduction

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

Hepatitis C Alcohol Reduction Treatment

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Influenza Vaccine in Lung Transplant Patients - Seroprotection

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.

Rapid Detection of Airway Pathogens for Lung Transplantation

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection

Viral Triggers in Pediatric Lung Transplantation

Comparison of Solid Organ Transplant

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)